[Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Who Have Already Visited Some Medical Institutions: The Points of Diagnosis and Treatment]. — CFSMEATLAS
[Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Who Have Already Visited Some Medical Institutions: The Points of Diagnosis and Treatment].
Shimomura, Tokio · Brain and nerve = Shinkei kenkyu no shinpo · 2022 · DOI
Quick Summary
ME/CFS is a debilitating condition characterized primarily by severe fatigue, but doctors currently have no reliable blood tests or biomarkers to definitively diagnose it. This editorial discusses how ME/CFS diagnosis and treatment require specialized medical knowledge, and notes that common treatments like vitamins and herbal medicines have not proven effective. The authors also observed ME/CFS-like symptoms in some COVID-19 patients, which has prompted renewed research into understanding how ME/CFS develops and finding better treatments.
Why It Matters
This editorial highlights critical gaps in ME/CFS diagnosis and treatment that directly affect patient care. The connection between post-COVID syndrome and ME/CFS raises important questions about shared mechanisms and may accelerate research efforts to find effective treatments, benefiting both groups of patients.
Observed Findings
ME/CFS lacks diagnostic biomarkers, requiring clinical diagnosis based on symptoms alone
ME/CFS diagnosis and treatment require highly specialized medical knowledge
Common treatments including Chinese herbal medicine, vitamins, and L-carnitine lack definitive evidence of efficacy
Some COVID-19 patients develop ME/CFS-like symptoms in the post-acute phase
Renewed research interest in ME/CFS mechanisms and treatments has emerged from post-COVID observations
Inferred Conclusions
Specialized medical expertise is essential for proper ME/CFS diagnosis and management given the absence of biomarkers
Currently available treatments for ME/CFS lack adequate scientific support
Post-COVID syndrome presents an opportunity to better understand ME/CFS pathophysiology
New research directions and mechanisms warrant investigation based on similarities between post-COVID and ME/CFS presentations
Remaining Questions
What specific biomarkers or diagnostic tools could be developed to reliably identify ME/CFS?
Are the mechanisms underlying post-COVID syndrome identical to those in ME/CFS, or do they represent distinct conditions?
What This Study Does Not Prove
This is an editorial review rather than original research, so it does not present new experimental data or clinical trial results. The observations about COVID-19 and ME/CFS-like symptoms are noted but not rigorously compared, and the editorial does not establish whether post-COVID syndrome and ME/CFS share identical underlying mechanisms.